| Date:   |  | -                        | 12/13/2021   |  |   |
|---|--|--------------------------|--|--|---|
| Your Name:  |  | _                        | Lance Baldo  |  |   |
| Ma  | nuscript Title:  | _                        | T -cell receptor sequencing identifies prior sequencing antibodies and disease severity  |  |   |
| Ma  | nuscript Number (if kı   | nown):                   | 150070-JCI-CC-1  |  |   |
| content of your manuscript. "Rela<br>affected by the content of the ma    |  | ipt. "Rela<br>of the mar | e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. |  |   |
| epi   |  | nsion, you               |  | example, if your manuscript pertains to the acturers of antihypertensive medication, even if |   |
| In item #1 below, report all supports frame for disclosure is the past 36 |  |                          |  | ithout time limit. For all other items, the time   |   |
|   |  |                          |  |  |   |
|   |  |                          | entities with whom you have this<br>hip or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution)          | 9 |
|   |  |                          | •  | made to you or to your institution)  | е |
| 1   |  |                          | hip or indicate none (add rows as needed)  Time frame: Since the initial planning  | made to you or to your institution)  | e |
| 1   | All support for the present manuscript (e.g., funding, provision   | relations                | hip or indicate none (add rows as needed)  Time frame: Since the initial planning  | made to you or to your institution) of the work  | e |
| 1   | All support for the present manuscript (e.g.,  | relations                | hip or indicate none (add rows as needed)  Time frame: Since the initial planning  | made to you or to your institution)  | e |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for | relations                | hip or indicate none (add rows as needed)  Time frame: Since the initial planning  | made to you or to your institution)  of the work  Click the tab key to add additional rows.  | e |

1 8/26/2021 ICMJE Disclosure Form

3

Royalties or

licenses

□ None

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | Adaptive Biotechnologies   | Equity ownership  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | □ None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | Adaptive Biotechnologies   | Leadership and employment   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Jim Boonyaratanakornkit  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None None  |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|    |  |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|--|---|
| 11 | Stock or stock options   |  | None   |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services |  | None   |   |
| 13 | Other financial or<br>non-financial<br>interests                                 |  | None   |   |
|    | Please place an "X" next to the following statement to indicate your agreement:  |  |  |   |

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date:  | 12/13/2021   |  |
|--|--|--|
| Your Name:   | Jonathan M. Carlson  |  |
| Manuscript Title:  | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |  |
| Manuscript Number (if known):  | 150070-JCI-CC-1  |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. |  |  |
| The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.   |  |  |
| In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months   |  |  |

Name all entities with whom you have this Specifications/Comments (e.g., if payments were made to you or to your institution) relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the □ None present manuscript (e.g., funding, provision of study materials, Click the tab key to add additional rows medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or □ None contracts from any entity (if not indicated in item #1 above). Royalties or □ None 3 licenses

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |   |     | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|-----|---|---|
| 11   | Stock or stock options  | Mic | None  | Equity ownership  |
|      |   |     |   |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services   |     | None  |   |
| 13   | Other financial or<br>non-financial<br>interests  | Mic | rosoft  | Employment  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |     |   |   |

|   | ICIVITE DISCLOSORE I ORIVI  |  |
|---|---|--|
| Date:   | 12/13/2021  |  |
| Your Name:  | Sudeb C. Dalai  |  |
| Manuscript Title:   | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity  |  |
| Manuscript Number (if known):   | 150070-JCI-CC-1   |  |
| content of your manuscript. "Rela<br>affected by the content of the ma<br>indicate a bias. If you are in doub!<br>The author's relationships/activitie<br>epidemiology of hypertension, you<br>that medication is not mentioned | In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time |  |
|   |   |  |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of  | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | □ None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | □ None   |   |
| 3 | Royalties or<br>licenses  | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|------|--|--|---|--|
| 11   | Stock or stock options   | □ None   |   |  |
|      |  | Adaptive Biotechnologies   | Equity ownership  |  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                     | □ None   |   |  |
| 13   | Other financial or<br>non-financial<br>interests   | Adaptive Biotechnologies   | Employment  |  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                                      |  |   |  |
| X    | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |  |

| Date:   | 12/13/2021   |  |
|---|--|--|
| Your Name:  | Rebecca Elyanow  |  |
| Manuscript Title:   | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |  |
| Manuscript Number (if known):   | 150070-JCI-CC-1  |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Time frame: Since the initial planning of the work  |  |   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | □ None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   |   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | □ None   |   |
| 3 | Royalties or licenses   | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 11 | Stock or stock options   | □ None  Adaptive Biotechnologies   | Equity ownership  |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services                      | □ None   |   |
| 13 | Other financial or<br>non-financial<br>interests   | □ None  Adaptive Biotechnologies   | Employment  |
|    | Please place an "X" next to the following statement to indicate your agreement:                                      |  |   |
| X  | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Michael Gale Jr.   |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|--|---|
| Time frame: Since the initial planning of the work |   |  | of the work   |
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).  | None None  |   |
| 3  | Royalties or<br>licenses  | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|      |  |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|--|---|
| 11   | Stock or stock options   |  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services   |  | None   |   |
| 13   | Other financial or<br>non-financial<br>interests   |  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:   I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |

| Date:  | 12/13/2021   |  |
|--|--|--|
| Your Name:   | Rachel M. Gittelman  |  |
| Manuscript Title:  | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |  |
| Manuscript Number (if known):  | 150070-JCI-CC-1  |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the |  |  |
| epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  |  |  |
| In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.  |  |  |

Name all entities with whom you have this Specifications/Comments (e.g., if payments were relationship or indicate none (add rows as needed) made to you or to your institution) Time frame: Since the initial planning of the work All support for the □ None present manuscript (e.g., funding, provision of study materials, Click the tab key to add additional rows medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or □ None contracts from any entity (if not indicated in item #1 above). Royalties or □ None 3 licenses

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 11 | Stock or stock<br>options  | □ None  Adaptive Biotechnologies   | Equity ownership  |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                     | □ None   |   |
| 13 | Other financial or<br>non-financial<br>interests   | □ None  Adaptive Biotechnologies   | Employment  |
|    | Please place an "X" next to the following statement to indicate your agreement:                                      |  |   |
| X  | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:  | 12/13/2021   |  |
|--|--|--|
| Your Name:   | Alex L. Greninger  |  |
| Manuscript Title:  | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |  |
| Manuscript Number (if known):  | 150070-JCI-CC-1  |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. |  |  |
| The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.   |  |  |
| In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.  |  |  |

Name all entities with whom you have this Specifications/Comments (e.g., if payments were relationship or indicate none (add rows as needed) made to you or to your institution) Time frame: Since the initial planning of the work All support for the □ None present manuscript (e.g., funding, provision of study materials, Click the tab key to add additional rows medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or □ None contracts from any entity (if not indicated in item #1 above). Royalties or □ None 3 licenses

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | □ None Abbott  |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | □ None   |   |
| 6  | Payment for expert testimony  | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | □ None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock<br>options   | □ None   |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services   | □ None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | □ None  Labcorp Abbott Merck Gilead  | Family employment Institutional support Institutional support Institutional support |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Michael R. Holbrook  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|---|---|--|---|--|
|   |   | Time frame: Since the initial planning of the work   |   |  |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None     ■ |   |  |
| 3 | Royalties or<br>licenses  | None   |   |  |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|      |   |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11   | Stock or stock options  |  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  |  | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  |  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Tien-Ying Hsiang   |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None None  |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|      |   |  | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|---|
| 11   | Stock or stock options  |  | None  |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  |  | None  |   |
| 13   | Other financial or<br>non-financial<br>interests  |  | None  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |   |

3 8/26/2021 ICMJE Disclosure Form

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Lichen Jing  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|---|---|--|---|--|
|   |   | Time frame: Since the initial planning of the work   |   |  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None None  |   |  |
| 3 | Royalties or<br>licenses  | None   |   |  |

|    |   |           | s/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None None |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|   |  |  | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|---|
| 11  | Stock or stock<br>options  |  | None  |   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests                                 |  | None  |   |
| Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |   |

| ICMJE DISCLOSURE FORM   |         |  |   |  |
|---|---------|--|---|--|
| Date:   |         | 12/13/2021   |   |  |
| Your Name:  |         | lan M. Kaplan  |   |  |
| Manuscript Title:   |         | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity   |   |  |
| Manuscript Number (if I   | known): | 150070-JCI-CC-1  |   |  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |         | ot-for-profit third parties whose interests may be not to transparency and does not necessarily //interest, it is preferable that you do so.  Example, if your manuscript pertains to the acturers of antihypertensive medication, even if |   |  |
|   |         | entities with whom you have this hip or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of the work   |   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | □ None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   |   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | □ None   |   |
| 3 | Royalties or licenses   | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 11  | Stock or stock options   | □ None  Adaptive Biotechnologies   | Equity ownership  |
|   |  |  |   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                     | □ None   |   |
| 13  | Other financial or<br>non-financial<br>interests   | □ None  Adaptive Biotechnologies   | Employment  |
| Please place an "X" next to the following statement to indicate your agreement: |  |  |   |
| ×   | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | David M. Koelle  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of  | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None □   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   | 5   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | Oxford Immunotec   | Reagent grant related to SARS-CoV-2 diagnostics                                     |
| 3 | Royalties or<br>licenses  | None None  |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None None  |   |
| 6  | Payment for expert testimony  | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None     ■ |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None   |   |

|        |  |  | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------|--|--|---|---|
| 11     | Stock or stock options   |  | None  |   |
| 12     | Receipt of equipment, materials, drugs, medical writing, gifts or other services   |  | None  |   |
| 13     | Other financial or<br>non-financial<br>interests   |  | None  |   |
| Plea 🖂 | Please place an "X" next to the following statement to indicate your agreement:   □ I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |   |

|   | ICMJE DISCLOSURE FORM   |   |               |  |  |
|---|---|---|---------------|--|--|
| Dat                                     | te:   | 12/13/2021  | 12/13/2021    |  |  |
| You                                     | ur Name:  | Thomas Manley   |               |  |  |
| Ma                                      | nuscript Title:   | T -cell receptor sequencing identifies prior neutralizing antibodies and disease severity |               |  |  |
| Ma                                      | nuscript Number (if k   | nown):150070-JCI-CC-1   |               |  |  |
| cor<br>affe<br>ind<br>The<br>epi<br>tha | In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |   |               |  |  |
|   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)   |   |               |  |  |
|   |   | Time frame: Since the initial planning  | g of the work |  |  |
| 1                                       | All support for the present manuscript (e.g., funding, provision  | □ None  |               |  |  |

of study materials, Click the tab key to add additional rows. medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or □ None contracts from any entity (if not indicated in item #1 above). 3 Royalties or □ None licenses

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|---|
| 11   | Stock or stock options   | □ None   |   |
|      |  | Adaptive Biotechnologies   | Equity ownership  |
|      |  |  |   |
| 12   | Receipt of equipment, materials, drugs,  | □ None   |   |
|      | medical writing,   |  |   |
|      | gifts or other services  |  |   |
| 13   | Other financial or non-financial   | □ None   |   |
|      | interests  | Adaptive Biotechnologies   | Leadership and employment   |
|      |  |  |   |
|      |  |  |   |
|      |  |  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                                      |  |   |
| X    | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Dat                                | e:   |        | 12/13/2021   |   |  |
|------------------------------------|--|--------|--|---|--|
| Your Name:                         |  |        | Damon H. May   |   |  |
| Ma                                 | nuscript Title:  |        | T -cell receptor sequencing identifies prior S<br>neutralizing antibodies and disease severity |   |  |
| Ma                                 | nuscript Number (if k  | nown): | 150070-JCI-CC-1  |   |  |
| con<br>affe<br>indi<br>The<br>epid | In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. |        |  |   |  |
|                                    | em #1 below, report<br>ne for disclosure is th   |        |  | ithout time limit. For all other items, the time                                    |  |
|                                    |  |        | entities with whom you have this hip or indicate none (add rows as needed)                     | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|                                    |  |        | Time frame: Since the initial planning   | of the work   |  |
| 1                                  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  | □ No   | one  | Click the tab key to add additional rows.   |  |
|                                    |  |        | Time frame: past 36 month  | s   |  |
| 2                                  | Grants or  | ☐ Noi  | ne   |   |  |

1 8/26/2021 ICMJE Disclosure Form

contracts from any entity (if not indicated in item #1 above).

Royalties or

licenses

□ None

3

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock<br>options   | □ None  Adaptive Biotechnologies   | Equity ownership  |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services   | □ None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | □ None  Adaptive Biotechnologies   | Employment  |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Chihiro Morishima  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None None  |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None None |  |

|   |  |  | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|---|
| 11  | Stock or stock options   |  | None  |   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests                                 |  | None None   |   |
| Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |   |

| ICMJE DISCLOSURE FORM   |   |  |   |
|---|---|--|---|
| Date:   | te: 12/13/2021  |  |   |
| Your Name:  |   | Harlan S. Robins   |   |
| Manuscript Title:   | <b>Manuscript Title:</b> T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |  |   |
| Manuscript Number (if k   | known):   | 150070-JCI-CC-1  |   |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |   |  |   |
|   |   | entities with whom you have this hip or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of  | of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | □ None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   |   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | □ None   |   |
| 3 | Royalties or<br>licenses  | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock options  | □ None  Adaptive Biotechnologies   | Equity ownership  |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  | □ None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | Adaptive Biotechnologies   | Leadership and employment   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Stacy Selke  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|  |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--|---|--|---|
| Time frame: Since the initial planning of the work |   | of the work  |   |
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 montl  | Click the tab key to add additional rows.   |
| 2  | Grants or contracts from any entity (if not indicated in item #1 above).  | None   |   |
| 3  | Royalties or<br>licenses  | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None      |  |

|      |   |  | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|--|---|
| 11   | Stock or stock options  |  | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  |  | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  |  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |

| ICIVIJE DISCLOSORE FORIVI  |   |   |  |
|--|---|---|--|
| Date:  | 12/13/2021  |   |  |
| Your Name:   | ne: Thomas M. Snyder  |   |  |
| Manuscript Title:  | pt Title: T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity  |   |  |
| Manuscript Number (if known):  | Manuscript Number (if known): 150070-JCI-CC-1   |   |  |
| content of your manuscript. "Re affected by the content of the maindicate a bias. If you are in double the author's relationships/activite epidemiology of hypertension, you that medication is not mentioned. In item #1 below, report all supports." | In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. |   |  |
| Name a   | Il entities with whom you have this   | Specifications/Comments (e.g., if payments were |  |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Time frame: Since the initial planning of the work  |  |   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | □ None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 months   | 5   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | □ None   |   |
| 3 | Royalties or<br>licenses  | □ None   |   |

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 11  | Stock or stock options   | Adaptive Biotechnologies   | Equity ownership  |
|   |  |  |   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services                                     | □ None   |   |
| 13  | Other financial or<br>non-financial<br>interests   | □ None  Adaptive Biotechnologies   | Employment  |
| Please place an "X" next to the following statement to indicate your agreement: |  |  |   |
| X   | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Anna Wald  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|---|---|--|---|--|
|   | Time frame: Since the initial planning of the work  |  |   |  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None None  | Click the tab key to add additional rows.   |  |
|   |   | Time frame: past 36 months   |   |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None     ■ |   |  |
| 3 | Royalties or<br>licenses  | None     ■ |   |  |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None      |  |

|      |   |      | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|------|--|---|
| 11   | Stock or stock<br>options   |      | None   |   |
| 12   | Receipt of equipment, materials, drugs, medical writing, gifts or other services  |      | None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | None |  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |      |  |   |

| Date:                         | 12/13/2021   |
|-------------------------------|--|
| Your Name:                    | Mark H. Wener  |
| Manuscript Title:             | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |
| Manuscript Number (if known): | 150070-JCI-CC-1  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Time frame: Since the initial planning of the work  |  |   |
|   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  Time frame: past 36 month  | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or licenses   | None   |   |

|    |   |           | c/Comments (e.g., if payments were or to your institution) |
|----|---|-----------|--|
| 4  | Consulting fees   | None None |  |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None      |  |
| 6  | Payment for expert testimony  | None None |  |
| 7  | Support for attending meetings and/or travel  | None None |  |
| 8  | Patents planned,<br>issued or<br>pending  | None None |  |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | None None |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                                       | None      |  |

|   |  |  | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|---|
| 11  | Stock or stock options   |  | None  |   |
| 12  | Receipt of equipment, materials, drugs, medical writing, gifts or other services |  | None  |   |
| 13  | Other financial or<br>non-financial<br>interests                                 |  | None  |   |
| Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |   |   |

3 8/26/2021 ICMJE Disclosure Form

| Date:  |   |   | 12/13/2021   |   |  |
|--|---|---|--|---|--|
| Your Name:   |   |   | H. Jabran Zahid  |   |  |
| Manuscript Title:  |   |   | T -cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity |   |  |
| Ma   | nuscript Number (if k   | nown):  | 150070-JCI-CC-1  |   |  |
| content of your manuscript. "Rela<br>affected by the content of the ma<br>indicate a bias. If you are in doub<br>The author's relationships/activiti<br>epidemiology of hypertension, yo<br>that medication is not mentioned |   | ipt. "Rela<br>of the man<br>e in doubt<br>s/activitionsion, you<br>entioned | rt for the work reported in this manuscript without time limit. For all other items, the time                                      |   |  |
|  |   | •   |  |   |  |
|  |   |   | l entities with whom you have this<br>ship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were |  |
| Time frame: Since the initial planning of the work   |   |   | ship of indicate none (add rows as needed)   | made to you or to your institution)             |  |
|  |   |   |  |   |  |
| 1  | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. |   | Time frame: Since the initial planning one   | Click the tab key to add additional rows.       |  |
| 1  | present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for                                 |   | Time frame: Since the initial planning   | Click the tab key to add additional rows.       |  |

any entity (if not indicated in item

#1 above).

Royalties or

licenses

□ None

3

|    |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4  | Consulting fees  | □ None   |   |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | □ None   |   |
| 6  | Payment for expert testimony   | □ None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel  | □ None   |   |
| 8  | Patents planned,<br>issued or<br>pending   | □ None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board                                | □ None   |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | □ None   |   |

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| 11  | Stock or stock options   | □ None   |   |
|   |  | Microsoft  | Equity ownership  |
|   |  |  |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services                      | □ None   |   |
|   |  |  |   |
|   |  |  |   |
| 13  | Other financial or<br>non-financial<br>interests   | □ None   |   |
|   |  | Microsoft  | Employment  |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
| Please place an "X" next to the following statement to indicate your agreement: |  |  |   |
| X   | I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |   |



Click on boxes to check/uncheck items.

# Checklist for submitting a revised Clinical Medicine manuscript

In addition to addressing the items noted in the decision letter regarding your manuscript, ensure that your revised manuscript adheres to the guidelines below. For full submission details, visit the ICI Insight website.

### **Required files**

#### Manuscript

PDF of a clean version of the entire manuscript, including Figures, Figure legends, and Tables PDF of a marked-up version of the entire manuscript showing revisions and prefaced by a point-by-point response to reviewer comments

Word or RTF file of all text of the submission, including Figure legends, Tables, Table legends, and References (without Figures, images, or point-by-point responses)

Single PDF file of completed ICMJE uniform disclosure forms from all authors

For clinical trials, PDF of the appropriate reporting checklist (CONSORT, STROBE. etc.)

#### **Figures**

Publication-quality figures in TIFF format. See detailed instructions for figure preparation. Recommended: Graphical abstract (details available here)

#### Supplemental material

Single file containing supplemental material, figures, and modest-sized tables, as:

(a) (if applicable) a PDF highlighting reviewer-requested changes

(b) a clean, publication-quality PDF

Upload any supplemental videos and/or large Excel files separately

#### Gels

APDF, PPT, or PPTX file (distinct from any other supplemental material) that shows the entire unedited gel

Clearly indicate which bands were used for the figures

# **Formatting**

Maximum 12,000 words (all text inclusive of title page, full text, references, figure legends, and tables)

Double-spacing throughout, including references and tables; figure legends may be single spaced if necessary to keep a figure and its legend on the same page

All pages numbered

Each section begins on a new page

#### Abbreviations and acronyms

Standard JCI Insight abbreviations and acronyms used without definition

All other abbreviations and acronyms spelled out at first use in the Abstract and again at first use in the main text (with the abbreviated form appearing in parentheses), and used without definition thereafter

#### Gene and protein names and symbols

Conform to official NCBI Gene Nomenclature

Presented according to JCI Insight Gene nomenclature and style

#### Italicization

Generally reserved for gene symbols, genotypes, and species names

Terms such as in vivo, in vitro, etc., are not italicized

# Unpublished data, manuscripts in preparation or under review, and personal communications

Cited parenthetically in the text, not as numbered references; e.g., "(Jane L. Doe, UCLA, Los Angeles, California, USA, unpublished observations)"

Written permission to cite unpublished observations of someone outside the author's research team (an email is sufficient) is submitted

#### **Reference citations**

Appear in parentheses preceded by a space, e.g., "as described previously (1, 2)"; "several research groups (4–10) have found"

No superscript, bold, italics, etc.

#### Figure and table callouts

Figures and tables called out in numerical order

"Figure", "Table", "Supplemental Figure", "Supplemental Table", etc., spelled out

Callouts in parentheses (no boldface or italics) unless grammatically part of the sentence: "the levels increased (Figure 5A)"; "data shown in Table 2"

Parts called out as follows: "Figure 1A", "Figure 2, A and B", "Figure 3, B-D"

## Manuscript preparation and required reporting

# Title page

#### Manuscript title

Clear, concise, and limited to 15 words, including conjunctions

Refers to the relevant disease or disease model studied

No subtitles, colons, periods, or nonstandard abbreviations

#### **Authors and affiliations**

Author names provided in full (for example, "Benita J. Sjögren") and in the appropriate order No titles, honorifics, degrees, or certifications

Author affiliations correspond to the period when the work was performed

For authors whose affiliation has changed since completion of the work, specify the present affiliation and location below the numbered list

Affiliation footnotes assigned consecutively using superscripted numbers (1, 2, 3, etc.)

Affiliations include departments, institutions, city, state (if applicable), and country (but not mailing addresses or zip/regional codes)

Corresponding author's complete name, address, telephone number (including country code if applicable), and email address

Consortium/study groups shown as authors (e.g., CARDIoGRAM Consortium)

Unless the members of the group appear as authors, each individual member and their affiliation are listed in the supplemental material, under the heading Supplemental Acknowledgments

The following sentence appears in Acknowledgments: "See Supplemental Acknowledgments for details on {name of consortium}."

#### **Conflict-of-interest statement**

A statement consistent with the Journal's conflict-of-interest policy is included; if no author has a conflict, state the following: "The authors have declared that no conflict of interest exists." If patents are involved, the patent or patent application number(s) are provided, and the names of the associated authors specified

#### **Abstract**

<u>Structured format</u> with the sections Background, Methods, Results, Conclusion, Trial registration, Funding

Maximum 250 words

No references

All nonstandard abbreviations defined at first use

### Main text (presented in the following order)

#### Introduction

#### Results

#### Discussion

#### Methods

Demographic reporting

Reporting on race and ethnicity adheres to NIH guidelines or other applicable authoritative standards

Descriptors for any demographic identities are clear, unbiased, and up-to-date

Data for any demographic variable are inclusive; if any information is unavailable or incomplete, an explanation is provided

Specify whether the participants or investigators made the classifications; and whether the options were defined by the investigators or participants

Complete manufacturer name (omit location) provided for each proprietary item used

For animal models, precise genotype, strain, number of backcrosses, sex, age, and source are specifed

Description of all antibodies used, including the source and catalog/clone number for commercial antibodies or (reference to) a description of the generation of custom antibodies Source of all cell lines used is indicated

Data sets for gene expression microarrays, SNP arrays, and high-throughput sequencing studies are deposited in a public repository, and accession number(s) provided in Methods the main text (for publication, data must be publicly available)

#### Statistics

Section appears near the end of Methods (before "Study approval")

The *P* value used to determine significance is specified; e.g., "A *P* value less than 0.05 was considered significant."

Analysis appropriately corrects for multiple comparisons (more than 2 groups) and for repeated measures (multiple measurements within subjects)

If samples were excluded, a statement describes inclusion/exclusion criteria

#### Study approval

Stand-alone paragraph at the end of Methods

Declaration of approval of human and/or animal studies, specifying the name and location of the appropriate institutional review board(s)

For human studies, a statement indicating receipt of written informed consent from participants and/or their parents/guardians

For use of photographs of patients, a separate statement of written informed consent

#### **Author contributions**

Contribution of each author (identified by initials) is specified

Grammatically complete sentences

For manuscripts with 2 or more co-first authors, the method used to assign authorship order among these authors is stated

#### Acknowledgments

States sources of support in the form of grants, equipment, or drugs Grant numbers provided as applicable

Other appropriate acknowledgments, such as of colleagues for advice

#### References

Styled according to Journal reference instructions

#### Figure legends

Maximum 300 words

Each begins with stand-alone title, irrespective of the individual parts

Figure parts called out in boldface: (A), (B-D), (C and E)

Symbols and abbreviations introduced in figures are defined

In each figure legend where appropriate, the statistical test(s) used is described

Variance around the mean and statistical analysis not provided for figures representing fewer than 3 independent samples

For figure panels representing multiple experiments, exact number of samples (n) is reported For representative experiments, the number of times the experiment was conducted is reported

For histological panels and insets, scale bars are defined or total original magnification is specified in the figure legends

#### **Figures**

Prepared according to Journal figure instructions

For clinical trials, the appropriate flow diagram appears as a figure

Parts labeled with capital letters: A, B, C, etc., with no designated subparts

Graphs of quantitative data presented as either dot plots, with average and appropriate error bars indicated; or box-and-whisker plots, with values defined in the legend (bounds of the boxes, lines within the boxes, whiskers, and any outlying values); dynamite plunger plots are not permitted

If lanes in a gel or blot image are spliced together into a composite image, the lanes are separated with a thin vertical line (black on gray background; white on black background); a note in the legend states that the lanes were run on the same gel but were noncontiguous

#### Tables

Prepared in Word table format (not pasted in from another application)

Self-contained and self-explanatory

Each table fits on a single page and is presented on its own page

Preceded by brief titles

Callouts to footnotes (designated with superscript capital letters) assigned alphabetically row by row

No subparts or subsections (for example, Table 1A and Table 1B)

Column headings in tables apply to all values throughout the column; a new row of column headings may not be introduced within a table

See "Methods" above for reporting on demographics

#### Supplemental material

A single PDF file includes all supplemental material except videos and spreadsheets. See "Methods" above for large data sets

Before submission, carefully review all supplmental files; they will not be checked by a copy editor. The Journal is not responsible for any errors contained in supplemental material.